COVID-19 Pandemic
Applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.
On this page you’ll find answers to frequently asked questions about mRNA vaccines.
All about the vaccines - briefly and concisely explained
Vaccines: Rapid solution for new diseases?
Swismedic - The way a vaccination works
How an mRNA vaccine works
How a vector vaccine works?
How a protein vaccine works
How is the safety of vaccines monitored?
Communication regarding COVID-19
18.12.2023
The manufacturer Novavax is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland
01.11.2023
Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3
28.09.2023
Spikevax XBB.1.5 approved for persons aged 18 and over
22.09.2023
Comirnaty XBB.1.5 approved for persons aged 12 and over
30.08.2023
Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5
21.08.2023
Recommendations Swissmedic / swissethics for the treatment of patients
19.07.2023
Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5
13.07.2023
Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5
11.04.2023
Bivalent Original / Omicron BA.4-5 mRNA vaccine (tozinameran / famtozinameran) approved
27.03.2023
Three formulations (authorisation nos. 68225 and 68710, with 30 and 10 μg/dose) authorised for five years
